Sweden's RaySearch Q2 order intake rises on clinical adoption

RaySearch Laboratories AB (publ)

13/08/2026 06:42

Overview
Sweden oncology software firm's Q2 net sales fell 11% yr/yr, organic growth at -8%
Adjusted EPS for Q2 declined to SEK 0.57 from SEK 0.90 yr/yr
Company repurchased shares worth SEK 142 mln to adjust capital structure

Outlook
RaySearch maintains its operating margin target of at least 25% for 2026
Company expects strong performance during the second half of the year
RaySearch sees continued strong demand for advanced radiation therapy software

Result Drivers
ORDER INTAKE - Co said Q2 order intake rose 23%, but several expected US transactions were delayed and received in early Q3
MARKET EXPANSION - Co highlighted strategically important orders in both existing and new markets, including Dana-Farber Cancer Institute (USA) and Tam Anh General Hospital (Vietnam)
CLINICAL ADOPTION - Advances in clinical use of RayStation and RayCare, including first online adaptive treatments in Belgium and UK

Company press release: ID:nMFNb1Q4wB

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Sales
 
SEK 272 mln
 
Q2 Adjusted EPS
 
SEK 0.57
 
Q2 Net Income
 
SEK 20 mln
 
Q2 Operating Profit
 
SEK 28 mln
 
Q2 Order Backlog
 
SEK 1.69 bln
 
Q2 Orders
 
SEK 296 mln
 

Analyst Coverage
The one available analyst rating on the shares is "strong buy"
The average consensus recommendation for the advanced medical equipment & technology peer group is "buy."
Wall Street's median 12-month price target for RaySearch Laboratories AB (publ) is SEK310.00, about 62.6% above its August 12 closing price of SEK190.70
The stock recently traded at 21 times the next 12-month earnings vs. a P/E of 20 three months ago

Reuters Recommended Reads
Aug 12 - Sweden's Magle Chemoswed Q2 revenue rises on improved production efficiencies
Aug 12 - Oncology device maker RenovoRx's Q2 revenue surges, raises FY outlook
Aug 12 - Kura Oncology Q2 product revenue rises 57% on KOMZIFTI uptake

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)